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ABSTRACT 
 
 
To investigate a novel route for providing analgesia to processed piglets via 
transmammary drug delivery, meloxicam was administered orally to sows after farrowing. The 
objectives of this study were to prove the transmammary delivery of meloxicam from sows to 
piglets, describe initial pharmacokinetic parameters and to characterize the analgesic effects in 
piglets after processing through assessment of pain biomarkers and infrared thermography (IRT). 
Ten sows received either meloxicam (30 mg/kg) (n=5) or whey protein (placebo) (n=5) in their 
daily feedings, starting four days after farrowing and continuing for three consecutive days. 
During this period, blood and milk samples from sows and piglets were collected at 12-hour 
intervals. On Day 5 after farrowing, three boars and three gilts from each litter were castrated or 
sham castrated, tail docked and administered an iron injection. Piglet blood samples were 
collected immediately before processing and at predetermined times over an 84-hour period. IRT 
images were captured at each piglet blood collection point. Plasma was tested to confirm 
meloxicam concentrations using a validated high-performance liquid chromatography-mass 
spectrometry method. Meloxicam was detected in all piglets nursing on medicated sows at each 
time point, and the mean (±standard error of the mean) meloxicam concentration at castration 
was 568.9 ±105.8 ng/mL. Sow plasma and milk, along with piglet plasma reached steady 
concentrations at 36 hours after the administration of meloxicam. Furthermore, ex-vivo 
prostaglandin E2 (PGE2) synthesis inhibition was greater in piglets from treated sows compared 
to controls (p=0.0059). However, button gastric ulcers and subacute gastritis were noted in 2/5 
meloxicam-treated sows and their litters.  Initial sow oral meloxicam pharmacokinetic 
parameters (±SD) were calculated including absorption rate constant (ka) of 0.13 (0.05) hr
-1
, 
volume of distribution (V) 149.65 (8.94) mL/kg, and clearance (Cl) of 18.86 (0.45) mL/hr/kg.   
ix 
 
There was a time-by-treatment interaction for plasma cortisol (p=0.0009), with meloxicam-
treated piglets demonstrating lower cortisol concentrations than control piglets for 10 hours after 
castration. No differences in mean plasma substance P concentrations between treatment groups 
were observed (p=0.67). Lower cranial skin temperatures on IRT were observed in placebo 
compared to meloxicam-treated piglets (p=0.015).  
Although there is great potential benefit to this method in the realms of analgesia, safety, 
and efficiency, dose refinement and a full understanding of pharmacokinetics of meloxicam by 
this route is needed before its application into swine. 
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CHAPTER 1.  GENERAL INTRODUCTION 
 
 Introduction 
 
The swine industry is experiencing increasing concern from producers and consumers  
regarding the well-being of food producing animals [1]. Pain management during routine piglet 
husbandry practices (also known as processing), such as castration and tail docking, is of 
particular concern. Over 112 million pigs were marketed in the US in 2013 [2] and in 2014 over 
2 million metric tons of pork were exported to other countries [3].  Practically speaking, half of 
those were castrated males and nearly all were tail-docked.   Although piglets have appeared to 
adapt to these husbandry practices, there continues to be requests from those whom work directly 
and indirectly with animal agriculture to consider pharmacological interventions to modulate 
acute and chronic pain.   
In the US, there are currently no Food and Drug Administration (FDA)-approved drug 
regimens for livestock pain relief in livestock and analgesia is not routinely provided at 
processing time.  Analgesics such as nonsteroidal anti-inflammatory drugs (NSAIDs), 
specifically injectable meloxicam, are approved in other countries for the relief of post-operative 
pain in swine with minor soft tissue surgery such as castration [4].  Oral meloxicam has been 
shown to provide analgesia to bovines at the time of castration [5,6], which logically leads to the 
application of the same concept in swine.  
Since piglets are castrated and tail-docked while still suckling milk from their dam, a 
novel manner of meloxicam administration would be through this route.  Administering oral 
meloxicam to sows during lactation would potentially provide analgesia during processing 
procedures by allowing passive drug transfer through her plasma, into the milk that in turn would 
be consumed by her piglets. This route is safer for both the handler and the animal when 
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compared to injections because there is no needle usage or entry into the sows farrowing stall. It 
is also easily administered and allows a large number of animals to be medicated at once, thus 
eliminating the need for individual injections. Although there are no peer-reviewed studies 
demonstrating transmammary analgesia in swine, NSAIDs have been shown to transfer through 
milk in both cattle [7]  and humans [8,9]. 
It is this void in the scientific knowledge that provided for this proof of concept study 
demonstrating the successful transfer of meloxicam from sows to piglets through milk at 
processing, with described effects of analgesia, pain biomarkers, and initial pharmacokinetic 
parameters.   
Thesis Organization 
This thesis is organized in journal paper format.  Chapter 1 includes a general 
introduction followed by a review of the literature.  Chapters 2 and 3 are the author’s research 
projects prepared in manuscript form for publication.  Jessica L. Bates was the primary 
researcher and author of all manuscripts with assistance from co-authors.  Chapter 4 is the 
general conclusions and implications of the conducted research. 
Literature Review 
Surgical castration and tail docking 
Historically, the castration of pigs has been carried out for the following benefits: 1) 
prevention of unwanted breeding 2) behavioral modification, and 3) improvement in meat 
quality [10,11].  Most pigs in the US are marketed at the cusp of age and weight for puberty 
induction. The potential exists for exhibiting reproductive behavior, which is detrimental to 
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market growth efficiency [10]. Intact males are more aggressive and have increased mounting 
behavior, which can result in health problems and physical characteristic problems, such as leg 
injuries [10]. These leg injuries and possible subsequent lameness, along with skin lesions are 
also painful and can detrimentally affect animal well-being. Finally, consumers, especially in the 
US, are averse to eating pork with “boar taint”, an unpleasant odor and flavor due to 
androstenone and skatole produced in the testicles [10].  Androstenone is a testicular steroid that 
accumulates in fat tissue manifesting a urine-like odor and skatole is a product of trytpophan 
breakdown in the gut exhibiting a fecal-like odor [11].   
Tail docking in piglets is also carried out to protect against tail biting.  Tail biting is 
considered to have multiple etiologies and previous work has considered physical (i.e. floor 
type), environmental, nutritional, and feeding management, over-crowding, gender, genetics, 
length of tail and lack of substrates [12].  Kritas and Morrison found an increased association 
between severity of swine tail bite lesions and lung abscesses, pleuritic lesions, and prevalence of 
external carcass lesions and carcass trimming at the abattoir [13]. Practices used on commercial 
farms include surgical docking (using side cutters or a sharp knife to remove the tail) or using a 
cautery iron to sever the tail.   
General measurement of pain 
It is a generally accepted thought that piglet castration and tail docking causes pain and 
distress [14-16]. Evidence based pain management in domestic animals depends on two factors: 
first, an ability to assess pain effectively and accurately under clinical conditions and, second, 
having the tools with which to alleviate the identified pain [17]. Research to date on pain 
assessment in animals has tended to use one of three approaches:  1) measures of general body 
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functioning such as food and water intake or weight gain, 2) measures of physiological responses 
such as plasma cortisol concentrations, and 3) measures of behavior such as vocalizations [18].   
 Pain biomarkers 
Several physiological parameters to castration pain have been measured, and these 
parameters are often termed pain biomarkers.  A biomarker is officially defined by National 
Institutes of Health as “a characteristic that is objectively measured and evaluated as an 
indicator of normal biologic processes, pathogenic processes, or pharmacologic responses to a 
therapeutic intervention” [19]. Biomarkers contribute knowledge about clinical pharmacology 
and provide a basis for the designing of clinical trials.  They expeditiously and definitely 
evaluate safety and efficacy while at the same time providing information for guidance in dosing 
and minimize inter-individual variation in response.  They may be especially helpful in “proof of 
concept trials” [19].  A recent systematic review of pain management during routine piglet 
processing procedures highlighted the need for additional validation of pain biomarkers in peer-
reviewed studies [20,21].  This thesis will describe the use of plasma cortisol, plasma substance 
P and infrared thermography in detail.   
Plasma Cortisol 
Glucocorticoids are secreted in response to a real or perceived stressor, such as castration, 
and are generally considered to be a stress indication [22].  Plasma cortisol has long been 
described in scientific literature as a standard physiological parameter to monitor at piglet 
processing [12,14,22-32]. Plasma cortisol concentrations are generally shown to peak at 30 
minutes after processing [14,21,23,24,29,31]. In light of the short lasting increase, Hay suggested 
that their measurement may not be relevant for monitoring sub-chronic or chronic pain [33]. 
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Piglet plasma cortisol does have limitations as an objective pain biomarker. For instance, 
stressors such as handling may cause an increase in plasma cortisol concentrations. However, 
research by Prunier et al. suggests that sham-castrated pigs have lower amplitudes and durations 
of plasma cortisol than castrated piglets [14], and these are likely to be connected to pain or 
tissue damage [31]. Until more pain biomarkers can be clearly described and validated, cortisol 
remains one of the most easily and accurately identifiable means of describing piglet pain.  
Substance P 
Substance P (SP) is a neuropeptide considered to function as a neurotransmitter or 
neuromodulator in both the central and peripheral nervous systems, as well as eliciting a variety 
of biological responses.  These include stimulation of smooth muscle contraction, exocrine and 
endocrine gland secretion and plasma extravasation, as well as being involved in the regulation 
of immune and inflammatory responses [34]. Substance P’s effects are localized in the primary 
sensory neurons and neurons intrinsic to the GI, respiratory, and genitourinary tracts [35]. These 
effects are also involved in the integration of pain and stress [36,37]. 
There is a singular peer-reviewed study describing the use of SP as a pain biomarker at 
piglet castration.  Sutherland et al. found no significant differences in SP levels between 
castrated and sham-castrated piglet [23].  However, in bovines, Coetzee et al. reported observed 
elevated SP levels in castrated calves compared to their non-castrated counterparts [6]. Although 
SP has the potential to accurately characterize physiological pain, further research is needed to 
determine its value in swine. 
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Other Plasma Pain Biomarkers 
Several other studies describe a variety of physiological pain indicators.  These include 
adrenocorticotropic hormone (ACTH)[14,38-40], serum amyloid A (SAA)[41-43], β 
endorphin[32,38,40], C-reactive protein[23,43], epinephrine[33] and lactate[14,25].   However, 
there is a lack of consistent data to make a compelling argument for the use of any one of these 
as an objective pain biomarker.   
Infrared thermography 
Infrared thermography (IRT) involves the measurement of infrared radiation emitted by 
an object, which allows the surface temperature to be determined [44].  Specialized cameras 
produce images that show temperature variation on a body surface by their representation on a 
colored scale.  Infrared thermography examines many aspects of thermal physiology, including 
injury and disease diagnosis [45].   Animals that are stressed or in pain can exhibit decreases in 
cutaneous temperature due to sympathetic nervous system activation, which causes 
vasoconstriction, shifting of the blood from the skin to the organs, and loss of heat in the 
periphery of the body [45,46].  
In swine, IRT was also used by Hansson et al. to measure temperatures at 24 hours after 
piglet castration. Piglet ear temperature was observed to be significantly higher in control piglets 
versus those given either lidocaine or a lidocaine/meloxicam combination. In that same study, no 
significant differences were observed when measuring the skin around the castration site [42]. 
This one-time measurement reflects the differences noted in this study up to 24 hours after 
castration but fails to provide a depiction of chronic piglet pain.  
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Schmidt et al. also investigated the use of IRT when determining disease states in sows 
and found the eye (near the medial and lateral canthus) and the back of the ear to show promise 
as locations for accurate measurement of sow temperature during disease states [47].   Wariss et 
al. also described the use of IRT to illustrate stress at the abattoir and potential to assess meat 
quality [48].They found ear temperature to be positively correlated with creatine kinase (CK) and 
blood temperature to be positively correlated with cortisol.  Higher temperature, CK, and cortisol 
values are all associated with higher levels of stress.     
Infrared thermography has  been shown to be a valuable tool for pain assessment in beef 
and dairy calves by non-invasively measuring autonomic nervous system responses to stress [49] 
during dehorning and castration [45,50]. It is a promising tool for application to determine acute 
and chronic pain in piglets at the time of castration.   
General anesthesia 
Once pain is objectively described, methods for its alleviation are applied.  Several 
methods of anesthesia and/or analgesia have been tested to determine the most effective manner 
of pain mitigation during piglet processing.  Some of these have more potential for practical 
application than others. General anesthesia is defined by a loss of consciousness in addition to 
loss of sensation, induced by a drug that acts on the central nervous system [51].  It can involve 
the use of inhaled or injectable agents. 
Inhalation anesthesia 
Inhalation anesthesia has several potential benefits, including a relatively brief induction 
time, short-term effects with reversibility, and needle-free administration [10]. However, many 
of these anesthetic agents are controlled drugs and necessitate specialized equipment, both of 
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which are reasons why it would not be practical for on-farm use. Additionally, these inhalation 
anesthetics may intensify the duration of handling and behavioral distress during castration, 
increase costs, and involve certain expanded legal and human safety regulations [10].    
Various inhalant anesthetic agents have been studied piglet anesthesia.  Walker et al.  
demonstrated isoflourane to have mixed success as an anesthetic and analgesic agent.  At 
castration, anesthetized piglets had less reaction measured by palpebral reflex compared to non-
anesthetized piglets, but no differences in physiological markers of pain were noted, such as 
ACTH and β endorphin values [38].  However, Schulz et al. observed no significant changes in 
plasma cortisol concentrations and deemed isoflorane to be ineffective in controlling piglet pain 
at castration [52] [53]. Nitrous oxide was characterized as effective at inducing anesthesia during 
piglet castration, but its analgesic effects were insufficient in preventing pain at that time [10].   
Sutherland et al. also applied CO2 inhalation anesthesia in combination with flunixin 
meglumine. However, neither of these applications markedly reduced the pain-induced distress 
caused by castration in pigs [23].  Plasma cortisol response was not reduced, SP was increased 
along time spent lying after post-operatively and increased high-frequency stress vocalizations at 
castration.  Advantages of CO2 according to Sutherland are the speed at which CO2 can be 
administered and then the piglet returns to consciousness, and the fact it is an unrestricted drug 
with no known drug residues [23].  Both Gerritzen et al. and Zimmerman et al. reported that CO2 
was not effective for castration, due to a significant increase in adrenaline and noradrenaline, and 
behavioral abnormalities indicative of stress such as open-mouth breathing and seizures [54,55].  
Kohler et al. also reported piglets displayed violent struggling, increased vocalization, elevated 
ACTH  and β endorphin levels when CO2 was used [40]. 
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Injectable Anesthesia 
Some of the earliest studies of general anesthesia by McGlone et al. involved the IV 
administration of xylazine, ketamine hydrochloride and glyceryl guaiacolate.  Twenty-eight 
percent of two-week old piglets died within 24 hours of administration.  When the same protocol 
was repeated with 6 to 7 week old piglets, there was 0% mortality, although they nursed 1.5 less 
times in the 3-hour period post castration, compared with other piglets that did not receive 
general anesthesia [56].   
Other early attempts at alleviating piglet pain at castration include butorphanol 
administered IV to 8-week-old piglets. Although this analgesia reduced feeding time and weight 
gain in castrated piglets compared to non-castrated counterpart, this research demonstrated  no 
measurable behavior changes (in the form of reduced suckling and standing times, along with 
increased lying times) between those groups [16].  
Azaperone, a sedative labeled for swine in Europe, has been used pre-operatively to 
diminish stress and painful reactions of piglets at castration whether alone [57] or combined with 
ketamine [58].  However, work by Driessens et al. reported that azaperone decreased the 
intensity of vocalizations (in decibels) during physical castration in one-week old piglets 
compared to their non-treated castrated counterparts, rather than providing analgesia.  Schmidt et 
al. reported piglets castrated with azaperone exhibited increased a 200% increase in time away 
from the sow teat area [58].   
Local Anesthesia 
The use of local and topical analgesics during piglet castration has also been explored.  
Cutting and/or tearing of the spermatic cord has been shown to be the most painful part of 
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castration [15], Several local anesthesia products have been tested. Lidocaine is a membrane 
stabilizer that abolishes the ability of an electrical stimulus to elicit an action potential and 
therefore prevents pain stimuli to reach the central nervous system [59].    Ranheim et al. 
demonstrated after an intratesticular injection of lidocaine, drug concentrations reached peak 
levels at three minutes post-injection [60]. Lidocaine decreased pain responses in piglet 
castration when administered pre-castration.  Castrated piglets had a lower frequency of 
vocalizations (Hz) and less resistance movements compared to their non-lidocaine counterparts.   
due to the significant decrease in vocalizations during castration [25,42,61] and plasma cortisol 
levels [25]. Lidocaine injected on each side of scrotum, then 10 minutes later intratesticularly, 
was found effective for decreasing pain-associated behaviors, such as lying, huddling, and 
eating, in 2-week-old piglets [56].  
Topical anesthesia has the potential to reduce needle use and the need to handle piglets 
twice (once for local administration, then for the actual act of castration) [62]. Topical cryogen 
spray and local procaine hydrochloride with epinephrine were found to be ineffective at reducing 
plasma cortisol levels prior to castration in castrated piglets compared to non-castrated piglets 
[26] in castrated piglets compared to non-castrated piglets.  Sutherland et al. used short-acting 
(cetacaine, benzaine, butamben, and tetracaine hydrocholoride) and long-acting 
(lignocaine,bupivacaine, andrenaline, and cetrimide) topical anesthetics but both were ineffective 
in reducing cortisol levels and percentages of stress vocalization in  castrated piglets compared to 
those who were sham castrated. Additionally, piglets receiving the short acting topical anesthetic 
had worse wound healing scores at the surgical site 9 and 14 days post-castration. [62]. 
A product called Barrier Wound Spray® has been marketed for use at piglet castration.  It 
contains 2% of both lidocaine and povidone iodine [63], however, there is little peer-reviewed 
11 
 
data to support its use.  In one study by Hawkins et al. no observed differences in behavioral pain 
were noted in piglets at castration, although there is potential for increased wound healing [64].  
Nonsteroidal Anti-Inflammatory Drugs 
Nonsteroidal anti-inflammatory drugs, or NSAIDs, by definition are a group of drugs that 
have analgesic, antipyretic, and anti-inflammatory properties, due to their ability to inhibit 
prostaglandin synthesis [65].  NSAIDs are advantageous as pain management tools, for example, 
these advantages include a longer duration of effect, anti-inflammatory and analgesic activity, 
minimal behavior effects, lack of cardiorespiratory effects, readily available oral formulations, 
non-controlled drug status, and a license for use in food animals in other countries [66]. 
The development of NSAIDs with analgesic properties in the last two decades has 
revolutionized analgesia [17]. Early attempts at alleviating piglet pain at castration include oral 
aspirin, which demonstrated no measurable effects on piglet time spent drinking, lying, and 
standing post-castration[16]. Paracetamol, administered as a rectal suppository, was also 
demonstrated to provide effective post-operative analgesia in piglets using physiological 
biomarkers such as temperature, heart rate, respiratory rate, and blood pressure.  However, 
paracetamol’s half –life is relatively short at 62 minutes [67] compared to meloxicam (8 hours) 
[68].    
Tolfenamic acid is another NSAID with potential for pre-emptive use in piglet castration.  
However, it has not been widely documented and when published, results are mixed.  Zoels et al.  
showed a reduction in piglet cortisol after castration [29], however, Wavreille et al. demonstrated 
conflicting results with an increase in plasma cortisol post-castration, when compared to 
meloxicam and sham treated groups [69].  Finally, research by Zoels et al. showed both 
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tolefenamic acid and meloxicam reduced piglet plasma cortisol levels postsurgical after piglet 
castration with no difference between these two products [29].   
Flunixin meglumine (FM) has also been examined as a route of analgesia in piglet 
processing.  Marketed under the trade name of Banamine-S® (Merck Animal Health), it is 
labeled as an antipyretic agent in swine [70]. Sutherland et al. lists the advantages of FM as IM 
administration, its approved use in swine (Banamine-S®), and can be easily administered by 
trained staff with only one handling of the animal [23]. When administered both pre-and 
immediately post-castration, FM decreased the cortisol levels out to an hour post-castration 
[24,27,71] and stress calls of piglets [24] when compared to those receiving no analgesia.  
However, this same study also demonstrated that wound healing was significantly delayed in 
analgesic-treated groups out to four days post-castration [24].  In addition, it has been shown that 
FM has evidence of macroscopic and histopathological injection site lesions, causing much more 
significant damage than meloxicam [72].  
Ketoprofen has also been investigated in piglet castration.  It is labeled for use in swine in 
Canada for the treatment of fever and inflammation associated with respiratory infections [73]. 
Von Sonja et al. indicated that administration 10-30 minutes pre-castration reduced  plasma 
cortisol and ACTH  concentrations when compared to controls [39].  Cassar et al. supported 
these findings with a decrease in plasma cortisol at 90 minutes post-castration using ketoprofen 
[74].                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
Meloxicam 
Meloxicam is a NSAID of the oxicam class[75]. It is approved for swine in the EU and 
Canada for several conditions, including non-infectious locomotor disorders to reduce the 
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symptoms of lameness and inflammation, the adjunctive therapy in the treatment of MMA 
(mastitis-metritis-agalactia syndrome), and the relief of post-operative pain associated with 
minor soft tissue surgery such as castration[4]. 
Mechanism of Action 
Meloxicam’s mechanism of action involves a disruption in the inflammatory cascade, 
inhibiting the production of prostaglandins and other inflammatory mediators [67].  When cell 
membranes are damaged due to a trauma or painful stimulus, there is a release of arachidonic 
acid. Arachidonic acid is a substrate for prostaglandins, including PGE2 and cyclooxygenase 
(COX).   
PGE2 is an endogenous pyrogen, leading to upward resetting of the temperature 
regulating center in the anterior hypothalamus [76].  PGE2 can also synergize with primary 
inflammatory mediators such as histamine and bradykinin to cause hyperalgesia and allodynia.  
The net effect is a sensitization of pain receptors, thus lowering the pain tolerance threshold.  In 
response to an effective analgesic, PGE2 plasma concentrations are reduced, providing decreased 
nociocepetion following noxious stimulus.   
Cyclooxygenase exists in isoforms.  Cyclooxygenase-1(COX-1) is present constitutively 
in most types of cells and has numerous functions in homeostasis, including blood clotting, 
regulation of vascular integrity, and protection of the renal and gastric endothelium.  
Cyclooxygenase-2 (COX-2) is inducible at the cellular level and found at sites of inflammation, 
producing pro-inflammatory effects.  Meloxicam is relatively specific for the COX-2 isoform, 
which is believed to play the major role in inflammation.  A third isoform, cyclooxygenase-3 
(COX-3), recently described in the central nervous system of the dog,  is a spliced COX-1 
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variant and has been postulated to be responsible for some of the analgesia produced by NSAIDS 
[77].    
Newer NSAIDS, such as meloxicam, with partial specificity for COX-2 inhibition, are 
termed COX-2 preferential and those with no significant effect on COX-1 are described as COX-
2 selective[77].   Due to this specificity in meloxicam, the adverse effects due to inhibition of the 
housekeeping functions of COX-1, such as maintenance of renal and gastric mucosa and 
regulation of blood flow are avoided [67].    
Pharmacokinetics of Meloxicam 
NSAIDs, including meloxicam, are generally well absorbed after oral dosing due to their 
properties as weak organic acids and moderate-high lipid solubility.  As a general rule, the 
volume of distribution is  relatively low, particularly penetration of most NSAIDs into milk in 
the absence of mammary gland infection is poor, with milk concentrations being of the order of 
1% or less of plasma total (protein-bound plus free) concentration.  This results from the high 
degree of binding to plasma protein.  Distribution into milk is also limited by the Henderson-
Hasselbalch mechanism, as milk pH is less than that of plasma [76].   
Due to their weakly acidic nature, the elimination of most NSAIDs in urine varies with 
urine pH.  However, the overriding factor of this is the high degree of plasma protein binding of 
NSAIDs, which limits passage into glomerular ultrafiltate [76].   Meloxicam is cleared almost 
exclusively metabolically, with only low levels of parent compound detected in bile, urine, and 
feces.  Therefore, biotransformation governs the elimination of parent compound in all species.  
In a broad, species-comparative study, the main metabolites of meloxicam in humans, rates, 
mice, and mini-pigs was found to be a 5’-hydroxymethyl derivative and a 5’-carboxy derivative. 
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The excretion balance was similar to that in humans, with approximately on half of the dose 
being eliminated in the urine and one half in the feces [68].  
Analgesic Effects of Meloxicam 
Research shows ambiguous results when meloxicam is administered at the time of 
castration with some studies indicating a reduction in piglet pain while others describe no 
differences observed using analgesia.  Meloxicam had been reported to provide effective post-
operative pain relief when compared with paracetamol in the manner of reducing a global pain 
score, consisting of piglet lameness, vocalization, and restlessness [67]. However, Reiner et al. 
found no observed differences between piglets treated with NSAIDs (meloxicam and FM) post 
castration [24]. Piglet plasma cortisol levels and vocalization of all groups were all higher than 
non-castrated controls, and piglets with analgesics had slower wound healing time than those that 
did not[24]. Despite these perioperative studies, when given preoperatively meloxicam was 
demonstrated to significantly reduce plasma cortisol concentrations compared to piglets not 
given analgesia [27-29,78].   
Meloxicam also has an indirect on effect piglet well-being by directly affecting sow 
health and welfare.  It is labeled in the EU and Canada for the adjunctive therapy of septicemia 
and toxemia associated with mastitis-metritis-agalactica syndrome (MMA) [4].  The 
pathogenesis of MMA involves bacterial endotoxins acting to release mediators of acute 
inflammation such as prostaglandins. As previously noted, meloxicam inhibits the production of 
such inflammatory mediators.  Additional studies have demonstrated that meloxicam 
administered to the sow at farrowing decreases preweaning mortality [79-81], reducing the 
mortality rate by over 50% in litters of sows affected with MMA [81].  Most notable was the 
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30% reduction of piglet mortality rate in sows requiring farrowing assistance. This supports the 
theory that sows suffer from post-labor pain causing distress and decreased care for their piglets 
[79]. Nonsteroidal anti-inflammatory drug treatment such as meloxicam after birth could 
improve sow welfare and piglet survival [79].   
When production parameters are analyzed, studies demonstrated no increases in average 
daily gain and piglet feed consumption [25,28] when meloxicam is given pre-or pericastration.  
However, in herds where MMA may be clinical or subclinical, meloxicam has been shown to 
significantly increase piglet average daily gain, with meloxicam being superior to both FM [82] 
and tolfenamic acid [80]. 
Transmammary Drug Transfer  
Normal Swine Lactational Physiology 
The transmammary route provides a unique opportunity for piglet medication during 
regular feeding.  Piglets suckle approximately every 45-50 minutes and the mammary gland 
refills back to capacity within 35 minutes [83].  Piglets may stimulate milk let down for a period 
of minutes through nuzzling the mammary gland, but actual milk ejection from the gland is only 
about 15 seconds [83].  At the end of gestation and during the colostral phase, the junctions 
between epithelial cells surrounding the alveoli are not tight.  This allows serum transudate to 
leak from the bloodstream into the mammary secretions and milk components from the 
mammary gland alveoli to leak back to the bloodstream [84].  Despite the fact that the colostral 
phase is ending at the latest by 24 hours after parturition, there is still potential for the mammary 
epithelium to have the ability to pass drugs through to the milk.  Due to the continuous cycle of 
lactation, there is great potential to medicate baby piglets with an analgesic for several days.   
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Swine Transmammary Drug Transfer 
Aside from the work reported in this thesis, no current peer-reviewed literature describes 
the transfer of any drug via the transmammary route after oral administration in swine.  A recent 
National Pork Board report describes, research that found that injectable meloxicam is 
transferred through the milk to piglets at processing [85]. However, this transfer utilized a one-
time intramuscular dose of 1 mg/kg meloxicam to each sow, which resulted in 2.647 ng/mL of 
meloxicam in the piglet serum at 5 hours after administration [85]. Piglet plasma meloxicam 
levels in this  report were only measured out to this time point.  The combination of oral 
administration to sow with lactational transfer to piglets has to this point not been described.    
Transmammary Drug Transfer in Other Species 
In the absence of swine data, other species can be used to demonstrate the possible effects 
of transmammary NSAID transfer.  Meloxicam has also been indicated to transfer through 
placenta and milk in rats. After oral dosing with a radioactively marked meloxicam (5 
mg/kg/day), steady state conditions were achieved by the third dose. Radioactively-marked 
meloxicam was used to study elimination in rat milk nursing 9 to-11 day pups. Oral 
administration (5 mg/kg/day) resulted in higher concentration of radioactivity in milk than 
plasma at 5 hours and 24 hours post dosing. Sixty to 70% of radioactivity in the milk was 
associated with the unchanged parent compound [68]. There was a curious pharmacokinetic 
gender difference in that study. Although identical initially in distribution phase, female rats 
demonstrated considerably higher meloxicam concentrations compared to male rats. Female rat 
area under curve (AUC) was 217 mg*eq*hr/L and male rat AUC 70.9 mg*eq*hr/L, resulting 
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from a slower rate of elimination. Elimination half-life of meloxicam in females was more than 
double that of males (37 hours vs. 13 hours) [68].   
Malreddy et al. established that meloxicam administered orally to dairy cows at 1 mg/kg 
did have discernible milk levels out to 80 hours after administration. The mean (±SD) plasma 
Cmax and Tmax for meloxicam were 2.89 ± 0.48 μg/mL and 11.33 ± 4.12 hours, respectively, 
while the mean (±SD) milk Cmax and Tmax for meloxicam were 0.41 ± 0.16 μg/mL and 9.33±3.11 
hours, respectively.   
Human lactation has the largest body of research observing the transfer of NSAIDs to 
breast milk. Since analgesics are often administered to women after childbirth, whether for a 
Caesarian section or other painful procedure, there is often a concern regarding the possible 
transfer of these medications to infants.   Studies demonstrate mean milk doses of NSAIDs 
(weight adjusted with maternal doses) to be ranging from 0.16%-0.60% of the maternal doses 
[8,9,86,87].  These studies included the investigation of oral dosing of ketoprofen, celecoxib, and 
ketolorac tromethamine. All of these studies concluded these levels would be much below the 
toxic dose for infants.   
Drug transfer into human milk is largely a function of lipophilicity, molecular weight, 
protein binding,  negative logarithm of the acid dissociation constant (pKa), and maternal plasma 
concentration[8].  The amount of most NSAIDs in milk are expected to  be low because they are 
weak acids, lipid-soluble, and mostly protein-bound in plasma [86]. Despite extensive literature 
searches, an accurate amount of the milk consumed by piglets is difficult to estimate, along with 
the pharmacokinetics of any NSAID in the lactating sow.   However, much as in swine, during 
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the early human postnatal period, the tight junctions between lactocytes are underdeveloped.  
Thus, the potential elevations of milk/plasma ratios are suspected [8].  
A thorough review of the scientific literature demonstrates there is a need for and great 
opportunity to explore further the area of piglet castration analgesia.  Combining an established 
analgesic drug, such as meloxicam, in a novel route using exciting knowledge about pain 
measurement and lactation establishes the foundation for new research in the areas of 
pharmacokinetics and pain biomarkers.   
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Abstract 
To investigate a novel route for providing analgesia to processed piglets via 
transmammary drug delivery, meloxicam was administered orally to sows after farrowing. The 
objectives of this study were to prove the transmammary delivery of meloxicam from sows to 
piglets and describe initial pharmacokinetic parameters. Ten sows received either meloxicam (30 
mg/kg) (n=5) or whey protein (placebo) (n=5) in their daily feedings, starting four days after 
farrowing and continuing for three consecutive days. During this period, blood and milk samples 
from sows and piglets were collected at 12-hour intervals. On Day 5 after farrowing, three boars 
and three gilts from each litter were castrated or sham castrated, tail docked, and administered an 
iron injection. Piglet blood samples were collected immediately before processing and at 
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predetermined times over an 84-hour period. Plasma was tested to confirm meloxicam 
concentrations using a validated high-performance liquid chromatography-mass spectrometry 
method. Meloxicam was detected in all piglets nursing on medicated sows at each time point, 
and the mean (±standard error of the mean) meloxicam concentration at castration was 568.9 
±105.8 ng/mL. Sow plasma and milk, along with piglet plasma reached steady concentrations at 
36 hours after the administration of meloxicam. Furthermore, ex-vivo prostaglandin E2 (PGE2) 
synthesis inhibition was greater in piglets from treated sows compared to controls (p=0.0059). 
However, button gastric ulcers and subacute gastritis were noted in 2/5 meloxicam-treated sows 
and their litters.  Initial sow oral meloxicam pharmacokinetic parameters (±SD) were calculated 
including absorption rate constant (ka) of 0.13 (0.05) hr
-1
, volume of distribution (V) 149.65 
(8.94) mL/kg, and clearance (Cl) of 18.86 (0.45) mL/hr/kg.   Although there is great potential 
benefit to this method in the realms of analgesia, safety, and efficiency, dose refinement and a 
full understanding of extra-label drug use regulatory issues is needed before its application into 
swine.   
Keywords: meloxicam, swine, lactation, castration, analgesia 
Introduction 
Pork producers and consumers are increasingly concerned about livestock well-being. 
The management of pain during routine swine husbandry practices, such as castration and tail 
docking in piglets, is of particular concern. The European Union (EU) recently legislated to 
ensure that all piglets are castrated using analgesia/anesthesia. However, in the United States, 
there are currently no Food and Drug Administration (FDA)-approved drug regimens for 
livestock pain relief, and analgesia is not routinely provided at the time of processing.  
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Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) that is approved for swine 
in the EU and Canada for several conditions, including the relief of post-operative pain with 
minor soft tissue surgery [1]. When injected before piglet castration, meloxicam reduces serum 
cortisol concentrations [2], [3], [4]. Meloxicam has also been shown to reduce behavioral signs 
that are associated with piglet distress at castration and is considered to be superior to other 
analgesics when assessing pain-related behavioral criteria [5].  
Administering oral meloxicam to sows during lactation could potentially provide 
analgesia during processing procedures by allowing passive drug transfer through the milk to 
entire litters. This route is safer for both the handler and the animal when compared to injections 
with a needle. It is also easily administered and allows a large number of animals to be 
medicated, thus eliminating the need for individual injections. Prior to this study, there were no 
peer-reviewed studies demonstrating transmammary analgesia in swine, although NSAIDs can 
transfer through milk in both cattle [6] and humans [7], [8], [9]. The objectives of this study were 
to prove the transmammary delivery of meloxicam from sows to piglets and describe initial 
pharmacokinetic parameters. The findings demonstrate the successful transfer of meloxicam 
from sows to piglets through milk and associated physiologic proof of analgesia after processing, 
The effectiveness of this transfer is supported by a decrease in plasma PGE2 levels. Preliminary 
sow pharmacokinetic parameters are comparable to those previously established [10].   
Materials and Methods 
Before the initiation of this study, all techniques regarding animal use, housing, handling, 
and sampling were approved by the Iowa State University Animal Care and Use Committee 
(IACUC # 8-12-7430-S). 
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Animals 
Ten Yorkshire x Landrace sows at approximately one week prior to farrowing (average 
weight of 277.3 kg ±1.6 standard error of the mean [SEM]) were obtained from a commercial 
swine farm. Upon arrival, each sow was given a thorough physical exam and confirmed to be 
healthy and pregnant by a veterinarian, and a unique numerical ear tag (Allflex Global Ear Tags, 
Allflex USA, Inc., DFW Airport, TX) was applied to the right ear. Sows were housed at the Iowa 
State University Animal Resource Station in accordance with recommendations outlined in the 
Guide for the Care and Use of Agricultural Animals in Agricultural Use and Research and 
Teaching [11]. Sows were placed in Quad- or Euro-style farrowing stalls (Thorp Equipment, 
Thorp, WI), depending on availability. Both stall types were equally represented in both 
treatment groups. Regardless of stall type, each sow was housed in a farrowing stall area 
measuring 0.6 m × 2.1 m. Quad and Euro stalls had piglet creep areas of 7.0 m2 and 6.4 m2, 
respectively. After farrowing, a heat lamp was provided on each side of the creep area in each 
stall for the piglets.  
Feeding and treatment administration 
Prepartum sows were hand-fed 1.6 kg of an organic corn/soybean meal diet, which was 
confirmed to be free of meloxicam, twice daily. This diet was compatible with the National 
Research Council’s nutrient requirements for lactating sows [12]. Intake was gradually increased 
ad-libitum after farrowing. Sows had free access to water at all times through a nipple waterer in 
their stalls. On Day 4 after farrowing, sow treatments began and continued for six days.  Sows 
assigned to the meloxicam-treatment group (n=5) received 30 mg/kg meloxicam (Meloxicam, 
Aurobindo Pharma, India, Batch X1513019-A, Expiration Date 2/2015), which was divided 
equally between two feedings at 0700h and 1600h. The meloxicam was ground from tablets into 
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a powdered consistency using a commercial grinder (Spice & Nut Grinder, Cuisinart, East 
Windsor, NJ), after which it was incorporated into each sow’s daily feed ration in a portable 
mixer (Kobalt Model #043206, Monarch Industries, Winnipeg, MB, Canada). Control sows 
(n=5) received 30 mg/kg of whey protein placebo (Health Watchers, Inc., Bohemia, NY), which 
is a pharmacologically inactive excipient used in the manufacturing of meloxicam tablets. The 
placebo was prepared in a separately marked bucket by thorough hand-mixing with gloved hands 
to prevent cross contamination.  
Animal phase study design 
The sows were allowed to farrow naturally without induction methods. They were then 
randomly assigned to two groups. The first sow to give birth was allocated to the meloxicam-
treated group (MEL), and the second sow was allocated to the whey placebo group (CONT). The 
alternating pattern continued for the remaining sows, based on the farrowing date. The day of 
farrowing was designated as “Day 0” for each sow and litter. The overall time scheme of 
activities, including drug administration and sample collection, is detailed in Figure 1.  
On Day 3, post-farrowing piglets in the litter were weighed and ranked in a descending order. In 
each litter, the heaviest three boars and three gilts were selected and ear tagged (Allflex Global 
Ear Tags, Allflex USA, Inc., DFW Airport, TX). The next three heaviest piglets, regardless of 
sex, were selected, tagged and deemed as sentinels to specifically measure the inhibition of 
plasma prostaglandin E2 (PGE2) levels and demonstrate the pharmacodynamic effect of 
meloxicam. In total, nine piglets per litter were tagged. Two litters did not have three live boar 
piglets. In those instances, all available boars were used as test piglets. In another litter, a male 
test piglet was laid on and subsequently died after being identified but before blood sampling 
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began. No other piglets were substituted into the test category. Cross-fostering was not 
performed at any phase of the study.  
Piglet processing occurred on Day 5 after farrowing. After a pre-processing blood draw, 
the boars were immediately castrated and tail-docked. They then received 1 mL (100 mg) iron 
IM (Ferrodex 100, AgriLabs, St. Joseph, MO). Castration was performed in accordance with 
standard swine industry practices by making two vertical incisions approximately 2-3 cm long in 
the scrotum with a number-ten scalpel blade and scalpel handle, marsupializing the testicles, and 
finally providing manual pressure on the spermatic cord until it separated from the piglet’s body.  
Piglet tails were docked to an approximate length of 2 cm using a pair of side cutters.  
Immediately after each piglet castration and tail docking, the scalpel blade, handle and side 
cutters were immersed in a dilute chlorhexidine mixture for disinfection between each piglet 
procedure per typical swine industry practice.  All castrations were performed by a single 
experienced swine veterinarian to minimize variation (JLB). Gilts were handled in a similar 
manner, and they also underwent tail docking and received iron.  
Immediately prior to the administration of meloxicam, each sow had blood sampled not 
only to confirm a lack of meloxicam in the blood, but also for serum chemistry and complete 
blood counts (CBC) analyses.  The serum chemistry and CBC testing was repeated on blood 
draws on both sows and piglets immediately prior to necropsy on Day 8.  These samples were 
analyzed at the Iowa State University Clinical Pathology Laboratory in accordance with the 
specific standards of the lab. 
Sow blood samples (8 mL/sample) were collected via the left or right jugular vein using a 
25.4-mm, 16-gauge hypodermic needle (Air-Tite Products, Virginia Beach, VA) and 12-mL 
Luer lock syringe (TycoHealth Care, Mansfield, MA). During blood collection, sows were 
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manually restrained in their stalls using a pig snare. Piglet blood samples (2 mL/sample) were 
collected using the left or right jugular vein using a 3.8-cm, 22-gauge hypodermic needle 
(TycoHealth Care, Mansfield, MA) and 3-mL syringe (TycoHealth Care, Mansfield, MA). These 
samples were obtained using physical restraint by placing the piglet in a supine position.  
On Day 8 after farrowing, sows were euthanized by a penetrating captive bolt, followed 
by exsanguination, and piglets were euthanized by blunt force trauma to the cranium, according 
to the American Veterinary Medical Association guidelines [13]. Necropsies were performed on 
the sows and processed piglets. The liver, kidney, gastric fundus, duodenum, 
semitendinosus/semimembranosus muscle, and fat were collected for analysis. 
Sample collection, processing, and analysis 
All drug concentrations in plasma were analyzed at the Iowa State University Veterinary 
Diagnostic Laboratory by the Iowa State University-Pharmacology Analytical Support Team 
(ISU-PhAST).  
Meloxicam analysis 
Blood for meloxicam analysis was placed in 10-mL and 3-mL heparinized blood 
collection tubes (BD Vacutainer, Franklin Lakes, NJ). Samples were centrifuged for 15 minutes 
at 1000 g at ambient temperature. The plasma was separated and placed into cryovials for storage 
at -80°C. 
Plasma concentrations of meloxicam were determined using high-performance liquid 
chromatography (HPLC) (Accela Pump and Autosampler, Thermo Scientific, San Jose, CA, 
USA) with mass spectrometry (MS) detection (LTQ XL, Thermo Scientific, San Jose, CA, 
USA). Plasma samples, plasma spikes, and plasma quality control (QC) samples (200 µL each) 
were treated with 1 M trichloroacetic acid (100 μL) after the addition of the internal standard, 
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piroxicam (10 μL of 10 ng/μL). The samples were vortexed for 5 seconds and centrifuged for 20 
minutes at 2000 g to sediment the precipitate. A portion of the supernatant (150 μL) was 
transferred to an injection vial that was fitted with a glass insert containing 100 μL of 1.9% 
ammonium hydroxide in 25% aqueous acetonitrile. The injection volume was set to 20 μL. The 
mobile phases consisted of 0.1% formic acid in water (A) and 0.1% formic acid in acetonitrile 
(B) at a flow rate of 0.250 mL/min. The mobile phase began at 40% B with a linear gradient to 
95% B at 4 minutes, which was maintained for 1.5 minutes, followed by re-equilibration to 40% 
B. Separation was achieved with a solid-core C18 column (KinetexXB -C18, 100 mm × 2.1 mm, 
2.6-µm particles, Phenomenex, Torrance, CA, USA) that was maintained at 45°C. Piroxicam 
eluted at 2.6 minutes, and meloxicam eluted at 3.3 minutes. A full scan MS of the 
pseudomolecular ions of piroxicam (m/z 332) and meloxicam (m/z 352) was used for analyte 
detection. The sum of the intensities of ions at m/z of 115 and 141 were used for meloxicam 
quantitation. The internal standard, piroxicam, was quantitated with the sum of the ion intensities 
at m/z of 95, 121, and 164. Sequences consisting of plasma blanks, calibration spikes, QC 
samples, and porcine plasma samples were processed in batches with a processing method that 
was developed in the Xcalibur software (Thermo Scientific, San Jose, CA, USA). The processing 
method automatically identified and integrated each peak in each sample and calculated the 
calibration curve based on a weighted (1/X) linear fit. Plasma concentrations of meloxicam in 
unknown samples were calculated by the Xcalibur software based on the calibration curve. 
Results were then viewed in the Quan Browser portion of the Xcalibur software. Fourteen 
calibration spikes were prepared in porcine plasma covering the concentration range of 1–20,000 
ng/mL. QC samples were prepared at concentrations of 15, 150, and 1500 ng/mL in duplicate 
with each set of samples. Calibration curves exhibited a correlation coefficient (R2) exceeding 
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0.997 across the entire concentration range. The QC samples at 150 and 1500 ng/mL were within 
2–8 % of their nominal values, and the low QC sample at 15 ng/mL differed from its nominal 
value by 10–15 %. 
PGE2 analysis 
PGE2 concentrations were determined using methods that were previously described by 
Giorgi et al. [14]. Briefly, fresh piglet blood was collected into sterile tubes containing heparin. 
To stimulate ex-vivo PGE2 production by monocytes, the heparinized whole blood was 
incubated for 24 hours at 37°C with 10 µg/ml lipopolysaccharide (LPS, derived from 
Escherichia coli 055:B5, Sigma Aldrich, St. Louis, MO), which was diluted in phosphate-
buffered saline (PBS). The first blood collection occurred prior to treatments and was divided 
into two equal aliquots: one was incubated with LPS, and the other was incubated with an 
equivalent volume of PBS. These aliquots were used as positive and negative controls. 
At the end of the incubation, all samples were centrifuged at 400 g for 10 minutes to 
obtain plasma: 200 μl of plasma were mixed with 800 μl of methanol (1:5 dilution) to permit 
protein precipitation. After a final centrifugation at 3000 g for 10 minutes, supernatants were 
collected and stored at -80°C.  
The concentration of plasma PGE2 was determined using an enzyme-linked 
immunosorbent assay kit (Cayman Chemical, Co, Ann Arbor, MI). The calculated coefficient of 
variation for intra-assay variability was 11.7%, and the inter-assay variability was 9.2%.  
Pharmacokinetic analysis 
Pharmacokinetic modeling used a population approach using Monolix (Lixoft, Version 
4.3.3, Orsay, France) to fit a one compartment open model with oral absorption in the sows, 
using previously published data [88]to inform the model.    Sow plasma meloxicam values were 
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analyzed and the parameters calculated include sow absorption rate constant (ka), volume of 
distribution (V), and clearance (Cl).    
Statistical analysis 
Data were analyzed using generalized linear mixed models fitted with the GLIMMIX 
procedure of SAS (SAS Institute Inc., Version 9.2). Treatment, procedure, time, and their 
interactions were used as fixed effects, whereas sow was a random effect, and piglet was the 
subject of repeated measures. A separate linear mixed model was run to study the effect of 
meloxicam concentrations on PGE2 by using Meloxicam_Levels as an explanatory variable. 
Baseline measurements were used as covariates in the above models. Model assumptions were 
considered to be appropriately met, based on diagnostics that were conducted on studentized 
residuals. Estimated least square means and corresponding standard errors, or 95% confidence 
intervals, are presented. A significant difference was considered to exist when p≤0.05, and a 
marginal difference was considered to exist when 0.05 < p≤0.10. Relevant pairwise comparisons 
were conducted when the significance of the interaction term was p≤0.10, using Tukey-Kramer 
adjustments as appropriate to avoid inflation of the Type I error rate due to multiple 
comparisons. Sow and piglet CBC and serum chemistry data was analyzed in a standard t-test 
using JMP (SAS Institute, Inc., Version 11.0, Cary, NC). 
Results and Discussion 
Plasma meloxicam concentration 
The primary objective of this study was to confirm that the transmammary route of 
administration is achievable in piglets and describe initial pharmacokinetic parameters.  
Meloxicam was detected in the plasma of all piglets in the MEL group at every time point after 
treatment commenced (Figure 2). The mean ±standard error of the mean (SEM) meloxicam 
40 
 
concentration at castration was 568.9 ±105.8 µg/mL. No meloxicam was found in the CONT 
piglet plasma. In a recent National Pork Board (NPB) report [15], Brown reported that 
meloxicam administered IM to sows at processing time of the piglets was transferred through the 
sows’ milk to piglet.  However, this transfer utilized a one-time intramuscular dose of 1 mg/kg 
meloxicam to each sow, which resulted in 2.647 ng/mL of meloxicam in the piglet serum at 5 
hours after administration. Piglet serum meloxicam levels in this NPB study were only measured 
out to 5 fours. Due to differences in routes of administration and study design, further 
comparisons cannot be made. 
Plasma meloxicam concentrations in both sow plasma, sow milk, and piglet plasma 
maintained steady-state concentrations for the duration of the treatment period.  Plasma 
meloxicam concentrations began to decline after 72 hours, when the treatment was discontinued 
in the feed.  It is important to note that sow plasma, sow milk, and piglet plasma meloxicam 
concentrations ran parallel to each other for the treatment period (Figure 2).  Figure 3 presents 
the individual plasma profiles for meloxicam administered to the five sows in the current study at 
a dose of 30 mg/kg PO.  In order to achieve the noted concentrations of meloxicam in piglet 
plasma, mean (±SEM) sow plasma concentrations at castration (24 hours after the start of 
administration) were 18,127.80 (2872.1) µg/mL.  This emphasizes the need to formulate a sow 
dose large enough to achieve analgesic levels in piglets.   
Table 2 describes the raw data relating meloxicam concentrations in piglet plasma, sow 
plasma, and milk. When considering the mean of all meloxicam concentrations, piglet plasma 
concentration is 1.1% of sow plasma and 16.5% of sow milk, while sow milk is 6.5% of sow 
plasma.  To illustrate the extremes, the sow with the highest plasma meloxicam concentration  
was compared to the sow with the lowest plasma meloxicam concentration. In all three cases, 
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piglet plasma was represented as a percentage of sow milk and sow plasma, as well as sow milk 
as a percentage of sow plasma. Interestingly, the sow with the highest plasma meloxicam also 
transferred the largest amount to the milk, but its piglets had a lower plasma concentration that 
the sow with the lowest plasma meloxicam concentration. This illustrates the variability in 
transmammary drug transfer and possible piglet clearance factors that are yet to be elucidated.  
Since this study was designed to prove the concept of transmammary meloxicam transfer, 
the appropriate sow dose was unknown. The dose for this study was extrapolated from estimates 
about swine lactation and data about transmammary transfer of meloxicam in dairy cattle [6].  
Due to the nature of NSAIDs such as meloxicam and known pharmacokinetics in other species, 
this large sow dose and resulting sow plasma concentration for effective piglet plasma 
concentration is expected.   Drug transfer into human milk is largely a function of lipophilicity, 
molecular weight, protein binding, negative logarithm of the acid dissociation constant (pKa), 
and maternal plasma concentration [8].  The amount of most NSAIDS in milk is expected to be 
low because they are weak acids, lipid-soluble, and mostly protein-bound in plasma [16]. 
However, as in swine, during the early human postnatal period, the tight junctions between 
lactocytes are underdeveloped.  Thus, the potential elevations of milk/plasma ratios are suspected 
[8].  
Human lactation has the largest body of research observing the transfer of NSAIDS to 
breast milk. Since analgesics are often administered to women after childbirth, whether for a 
Caesarian section or other painful procedure, there is a concern regarding the possible transfer of 
these medications to infants.   Studies demonstrate mean milk doses of NSAIDS (weight 
adjusted with maternal doses) to be ranging from 0.16%-0.60% of the maternal doses 
[8,9,16,17].  Malreddy et al. established that meloxicam administered orally to dairy cows at 1 
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mg/kg did have discernible milk levels [6].  These meloxicam concentrations in milk remained at 
low residue levels in the milk after plasma drug concentrations had fallen below effective levels 
[6].      
PGE2  
PGE2 was inhibited in MEL piglets as a result of treatment, demonstrating a treatment 
effect (p=0.0059) and differences (p<0.05) at each time point, with the exception of 24 hours 
after drug administration (p=0.0909) (Figure 4). However, using this analysis, there was no time-
by-treatment interaction (p=0.1763) or effect of time (p=0.6064).  
This inhibition of PGE2 by meloxicam was anticipated, as a result of the blockage of the 
arachidonic acid pathway and cyclooxygenase-2. Prostaglandins contribute to the amplification 
of pain signaling by increasing nociception sensitization [18]. As such, reducing PGE2 
concentrations would provide decreased nociception following noxious stimuli, such as 
castration.  Mean piglet plasma PGE2 concentrations in all piglets sampled ranged from 66.2–
719.9 pg/mL. These levels are much lower than those reported in equines (1.7 ng/mL), canines 
(329 ng/mL) and felines(0.7 ng/mL) [19]. No porcine comparisons are available in the literature. 
There are several potential explanations for the lower PGE2 levels. First, the piglets were 
relatively young and blood from these animals may not have fully responded to LPS stimulation. 
Second, other studies have used different strains of LPS or different amounts of E.coli that are 
needed for LPS production. Finally, ex vivo stimulation of whole blood was used, which may 
contribute to lower levels. Despite these species-specific differences, decreases in plasma PGE2 
were observed at most time points in MEL piglets compared to CONT piglets.  This suggests 
that meloxicam was successfully transferred through milk to piglets at concentrations that likely 
provided analgesia based on the demonstrated ex vivo inhibition of PGE2 production.  
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Side effects of meloxicam administration 
Health and wellbeing of sows and piglets was closely observed throughout the study.  No 
adverse clinical effects were noted in any animal throughout the entire duration of the study. Pre- 
and post-treatment CBC and serum chemistry testing were all within the normal levels for swine.  
MEL sows had elevated blood urea nitrogen concentrations (p=0.03), compared to CONT sows 
(23.2 mg/dL and 13.8 mg/dL, respectively), yet this value was still within the normal range for 
swine (6-30 mg/dL). It is important to note that no kidney lesions as result of meloxicam 
administration were found on histopathology exam. 
Both gross and histopathologic changes were noted in the gastrointestinal systems of 2/5 
MEL sow and their litters. The most prominent pathology in the sows was subacute, ulcerative to 
erosive, suppurative duodenitis.  In contrast, the pathologist concluded that gross gastric sow 
lesions and mild lymphcytic-plasmacytic gastritis were likely age-related and not of clinical 
significance.  Multifocal button gastric ulcers were observed in 10/11 piglets from these two 
MEL sows, along with multifocal, subacute suppurative gastritis with submucosal edema. The 
pathologist concluded the gastritis noted in 10/11 piglets in those litters and the duodenitis noted 
in the two sows was compatible with insult from high levels of NSAID treatment. No such 
lesions were noted in the control pigs.   
The most frequent and clinically significant side effects of NSAIDs reported in the 
research literature are the irritant, ulcerogenic erosive effects on the gastrointestinal tract [20]. 
Other potential effects include renal toxicity, hepatotoxicity, blood dyscrasias and delayed soft 
tissue healing.  It must be emphasized that clinical manifestations of toxicity do not occur in the 
great majority of animals receiving recommended dose rates of NSAIDs [20]. Modifications for 
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the protection of normal body function and safety must be balanced with an efficacious dose 
before application in the swine industry.   
Pharmacokinetic modeling 
Pharmacokinetic modeling was performed on the sow oral meloxicam dosing, describing 
absorption rate constant (ka), volume of distribution (V) and plasma clearance (Cl). Although 
there are important differences between study designs, the current study parameters were 
compared to the only other available published and peer-reviewed study describing meloxicam in 
sows [10]. The parameters (±SD) are described in Table 1.  The ka 0.13 hr
-1
 (0.05) was 
numerically similar to that reported by Pairis-Garcia et al. with a ka of 0.10 (0.03) hr
-1
.  The V 
was 149.65 (8.94) mL/kg and numerically less than Pairis-Garcia et al. at 425.0 (0.27) mL/kg. 
Plasma Cl was 18.86 (44.01) mL/hr/kg and slower than described by Pairis-Garcia et al. at 43.08 
(0.45) mL/hr/kg.  These comparisons are worth noting, however, due to several differences 
between the studies, further comparison would be misleading.  
Model limitations 
The construction of a pharmacokinetic model from this study has considerable 
limitations.  First of all, the model using the same mathematical template as the only other peer 
reviewed study by Pairis-Garcia et al[10]. Several important differences exist between that study 
and the current one.  The sows used in the Pairis-Garcia study were cull sows at the end of their 
reproductive lifecycle while the present study used farrowing and subsequently, lactating sows. 
The body condition and biological mechanisms noted in these types of sows are often quite 
divergent, which has potential to affect drug metabolism.  The most common reasons for culling 
sows are reproductive failure and lameness [21], which are often chronic conditions affecting or 
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a result of, diminished body condition.   Conversely, recently farrowed, lactating sows are 
generally in a much better body condition with more energy stores to feed a litter of pigs.   
Lactation creates in sows a very physiologically dynamic state, balancing the synthesis of 
milk for piglets with the changing sow metabolism.  Several biological mechanisms are causing 
the sow to repartition her fat stores to energy, all the while trying to maintain a consistent, 
upward feed intake after giving birth.  This is all occurring in the face of an immune system in 
flux during the farrowing and post-farrowing period.  In contrast, cull sows are generally 
assumed non-pregnant and non- or minimally-lactating.  Although they may be experiencing 
some systemic catabolism, this is considered more of a chronic, static biological state in cull 
sows.  These physiological differences make it is quite plausible that cull sows and lactating 
sows have potential to metabolize drugs differently. 
Finally, the dosing methods were very distinct between studies both in amount, timing 
and administration.  The current study incorporated the meloxicam tablets (30 mg/kg) ground 
into powder, mixed into the regular twice per day feeding, more accurately simulating the 
potential application of the practice on commercial sow farms.  Uneaten feed from each sow was 
removed from the feeder and weighed back, and the approximate weight was 24% per MEL sow 
and 21% per WHEY sow.  The exact drug concentration is known, but although mixing was 
performed the homogeneity of the feed is unknown. The Pairis-Garcia study utilized a one-time 
oral meloxicam dose (0.5 mg/kg), incorporating the meloxicam tablets into a ball of cookie 
dough, to which the sows had been trained using positive reinforcement.   This ensured each sow 
ate the entire dosage in that mixture.   
Several unknown factors preclude further pharmacokinetic analysis past the sow level.  
Although serial sampling characterized meloxicam levels in sow plasma, sow milk, and piglet 
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plasma, we are unable to fully describe piglet parameters.  First of all, once meloxicam is in sow 
plasma, it can be transferred to several compartments for elimination, such as milk, kidney and 
liver circulation.  It was beyond the scope of this study to accurately measure renal and hepatic 
elimination, therefore, the part they may play in overall pharmacokinetics is unknown.     
Secondly, it is also very difficult to estimate the amount of milk the piglets drank.  Piglets 
suckle approximately every 45-50 minutes and the mammary gland refills to back to capacity 
within about 35 minutes [22].  Piglets may stimulate milk let down for a period of minutes 
through nuzzling the mammary gland, but actual milk ejection from the gland is only about 15 
seconds [22].  The average sow milk production varies greatly with parity, nutrition, and litter 
size.  Bussiéres estimates that healthy sows with 11 piglets on a regular commercial ration can 
produce between 10.3 and 11.3 kg of milk per day [23].  However, this amount can vary greatly 
with parity, nutrition, health status and litter size.  Additionally, there is very little data to 
estimate the exact amount each piglet drinks per suckling time, therefore making the piglet dose 
of any drug extremely challenging to describe.   
Regulatory issues 
The lack of approved analgesics in swine presents a conundrum.  Veterinarians are 
charged in their oath [24] and the professional organizations of the American Veterinary Medical 
Association [25], and the American Association of Swine Veterinarians [26], to uphold animal 
welfare and reduce pain, yet there are no approved drugs available in the US. The Animal 
Medical Drug Use Clarification Act of 1994 and its regulations published at Title 21, Code of 
Federal Regulations, Part 530 (21 CFR 530)  makes provision for veterinarians to employ extra 
label drug use (ELDU)  under certain specific conditions within the context of a veterinary client 
patient relationship (VCPR) [27].  These provisions include  a lack of an approved animal drug 
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that is labeled for the condition and that contains the same active ingredient in the required 
dosage form and concentration, a careful diagnosis of disease, a substantially extended, 
scientifically supported withdrawal time, and proper identification of the treated animal(s).  
Approved animal drugs, approved human drugs, and animal drugs compounded from approved 
animal or human drugs are eligible to be used in this manner.  However, ELDU is limited to 
circumstances when the health of an animal is threatened, or suffering or death may result from 
failure to treat.  This means that ELDU to enhance production is not permitted [28].   
Caution must be exercised in the immediate application of transmammary meloxicam 
administration into commercial systems.  There is no established meat withdrawal to enable 
meloxicam-treated swine to enter the food chain.  Furthermore, ELDU in feed is expressly 
prohibited.  Finally, although meloxicam is approved for IM use swine in Canada and the EU 
relief of post-operative pain associated with minor soft tissue surgery, such as castration, the 
dosage is much less (0.4mg/kg) than that of this study (30 mg/kg) Given these scientific and 
regulatory constraints, the transmammary method is not practical at the present time in 
commercial swine systems. 
This pioneer study describes the first peer-reviewed report of the successful 
transmammary transfer of meloxicam in milk from sows to piglets. Efficacy was confirmed by a 
reduction in PGE2, and initial sow pharmacokinetic parameters were described.  The novel 
administration of analgesic drugs via transmammary transfer has significant potential benefits for 
the swine industry. As an entire litter can be medicated through the oral treatment of one sow, 
large numbers of piglets can receive pre-emptive analgesia without the need for additional 
handling and injections. This will also lead to reduced animal stress, improved safety for both the 
pig and handler, and a decreased potential for tissue lesions and drug residues when the 
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injections are removed. However, due to lack of meat withdrawal and ELDU regulations, this 
method is not recommended for present use in the swine industry. Overall, this study provides a 
foundation for future research investigations in meloxicam dose refinement, withdrawal periods, 
and other means of swine analgesia.   
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TABLE 1.  Individual sow pharmacokinetic parameter comparison between two sow oral 
meloxicam studies.  Bates et al. administered 30 mg/kg meloxicam BID incorporated into the 
daily ration of five sows, while Pairis-Garcia et al. administered 0.5 mg/kg meloxicam in a one-
time bolus incorporated into sugar cookie dough to six sows.  Absorption rate constant (ka), 
volume of distribution (V), and plasma clearance (Cl) (±standard deviation (SD)) are described 
below. 
 Mean ka (hr
-1
) 
(±SD) 
V_mean (mL/kg) 
(±SD) 
Cl_mean (mL/hr/kg) 
(±SD) 
Bates et al. 0.13 (0.05) 149.65 (8.94) 18.86 (44.01) 
Pairis-Garcia et al. 0.10  (0.03) 425.00 (0.27) 43.08 (0.45) 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 2. Mean meloxicam concentration at piglet processing in sow plasma, sow milk and 
piglet plasma.  To illustrate the extremes, the sow with the highest plasma meloxicam 
concentration was compared to the sow with the lowest plasma meloxicam concentration. In all 
three cases, piglet plasma was represented as a percentage of sow milk and sow plasma, as well 
as sow milk as a percentage of sow plasma.   
 
 
Mean Plasma 
Meloxicam 
(n=5) 
Highest Sow  
Plasma Meloxicam 
Lowest Sow  
Plasma Meloxicam 
Piglet Plasma (ng/mL) 569.8 606.5 743.7 
Sow Milk (ng/mL) 3459.3 3221.7 2012.8 
Sow Plasma (ng/mL) 53,091.6 65,611.5 44,788.4 
    
Piglet Plasma/Sow 
Plasma 1.1% 0.9% 1.7% 
Piglet Plasma/Sow 
Milk 16.5% 18.8% 36.9% 
Sow Milk/Sow Plasma 6.5% 4.9% 4.5% 
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FIGURE 1. Outline of study events for sows and their litters 
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FIGURE 2. Comparison of plasma and milk meloxicam concentrations from sows and their 
piglets treated with 30 mg/kg meloxicam. The mean (±SEM) meloxicam levels at 24 hours 
(piglet processing) were 568.9 ±105.8 µg/mL. No meloxicam was found in CONT piglet plasma.  
Sow and piglet plasma and sow milk meloxicam concentrations maintained relatively constant 
levels for the duration of the treatment period, and they began to decline only after 72 hours 
when the treatment was discontinued in the feed. 
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FIGURE 3.  Individual plasma profiles in six sows administered meloxicam per os at 30mg/kg.   
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FIGURE 4. Plasma PGE2 ± SE levels from meloxicam (MEL) - and whey placebo (CONT) - 
treated piglets. MEL piglets had a greater amount of prostaglandin E2 (PGE2) inhibition 
compared to their CONT counterparts (p=0.0059). All time points that are marked with a and b 
were significantly different (p<0.05). The exception was 24 hours after administration 
(p=0.0909).  
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Abstract 
To investigate a novel route for providing analgesia to processed piglets via 
transmammary drug delivery, meloxicam was administered orally to sows after farrowing. The 
objectives of the study were to demonstrate meloxicam transfer from sows to piglets via milk 
and to describe the analgesic effects in piglets after processing through assessment of pain 
biomarkers and infrared thermography (IRT). Ten sows received either meloxicam (30 mg/kg) 
(n=5) or whey protein (placebo) (n=5) in their daily feedings, starting four days after farrowing 
and continuing for three consecutive days. During this period, blood and milk samples were 
collected at 12-hour intervals. On Day 5 after farrowing, three boars and three gilts from each 
litter were castrated or sham castrated, tail docked, and administered an iron injection. Piglet 
blood samples were collected immediately before processing and at predetermined times over an 
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84-hour period. IRT images were captured at each piglet blood collection point. Plasma was 
tested to confirm meloxicam concentrations using a validated high-performance liquid 
chromatography-mass spectrometry method. Meloxicam was detected in all piglets nursing on 
medicated sows at each time point, and the mean (±standard error of the mean) meloxicam 
concentration at castration was 568.9 ±105.8 ng/mL. Furthermore, ex vivo prostaglandin E2 
(PGE2) synthesis inhibition was greater in piglets from treated sows compared to controls 
(p=0.0059). There was a time-by-treatment interaction for plasma cortisol (p=0.0009), with 
meloxicam-treated piglets demonstrating lower cortisol concentrations than control piglets for 10 
hours after castration. No differences in mean plasma substance P concentrations between 
treatment groups were observed (p=0.67). Lower cranial skin temperatures on IRT were 
observed in placebo compared to meloxicam-treated piglets (p=0.015). This study demonstrates 
the successful transfer of meloxicam from sows to piglets through milk and corresponding 
analgesia after processing, as evidenced by a decrease in cortisol and PGE2 levels and 
maintenance of cranial skin temperature.  
Keywords: castration, lactation, meloxicam, pain, swine, welfare 
Introduction 
Pork producers and consumers are increasingly concerned about the well-being of food 
producing animals. The management of pain during routine swine husbandry practices, such as 
castration and tail docking in piglets, is of particular significance. The European Union (EU) 
recently moved to ensure that all piglets are castrated using analgesia/anesthesia [1]. However, in 
the United States, there are currently no Food and Drug Administration (FDA)-approved drug 
regimens for pain relief in livestock, and analgesia is not routinely provided at the time of 
processing.  
59 
 
Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) that is approved for swine 
in the EU and Canada for several conditions, including the relief of post-operative pain with 
minor soft tissue surgery. When injected before piglet castration, meloxicam reduces serum 
cortisol concentrations [2], [3], [4]. Meloxicam has also been shown to reduce behavioral signs 
that are associated with piglet distress at castration and is considered to be superior to other 
analgesics when assessing pain-related behavioral criteria [5].  
Administering oral meloxicam to sows during lactation would potentially provide 
analgesia during processing procedures by allowing passive drug transfer through the milk to 
entire litters. This route is safer for both the handler and the animal when compared to injections. 
It is also easily administered and allows a large number of animals to be medicated, thus 
eliminating the need for individual injections. Although there are no peer-reviewed studies 
demonstrating transmammary analgesia in swine, NSAIDs can transfer through milk in both 
cattle [6] and humans[7], [8], [9]. The objectives of this study were to demonstrate the 
transmammary delivery of meloxicam from sows to piglets and to assess the pharmacodynamics 
and analgesic effects in piglets after castration. The findings of this study demonstrate the 
successful transfer of meloxicam from sows to piglets through milk and associated analgesia 
after processing, as evidenced by a decrease in cortisol and PGE2 levels and maintenance of 
cranial skin temperature.  
Materials and Methods 
Before the initiation of this study, all techniques regarding animal use, housing, handling, 
and sampling were approved by the Iowa State University Animal Care and Use Committee 
(IACUC # 8-12-7430-S). 
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Animals 
Ten Yorkshire x Landrace sows at approximately one week prior to farrowing (average 
weight of 277.3 kg) were obtained from a commercial swine farm. Upon arrival, each sow was 
confirmed to be healthy and pregnant by a veterinarian, and a unique numerical ear tag (Allflex 
Global Ear Tags, Allflex USA, Inc., DFW Airport, TX) was applied to the right ear. Sows were 
housed at the Iowa State University Animal Resource Station in accordance with 
recommendations outlined in the Guide for the Care and Use of Agricultural Animals in 
Agricultural Use and Research and Teaching[10]. Sows were placed in Quad- or Euro-style 
farrowing stalls (Thorp Equipment, Thorp, WI), depending on availability. Both stall types were 
equally represented in both treatment groups. Regardless of stall type, each sow was housed in a 
farrowing stall area measuring 0.6 m × 2.1 m. Quad and Euro stalls had piglet creep areas of 7.0 
m2 and 6.4 m2, respectively. After farrowing, a heat lamp was provided on each side of the 
creep area in each stall for the piglets.  
Feeding and treatment administration 
Prepartum sows were hand-fed 1.6 kg of an organic corn/soybean meal diet, which was 
confirmed to be free of meloxicam, twice daily. This diet was compatible with the National 
Research Council’s nutrient requirements for lactating sows[11]. Intake was gradually increased 
ad-libitum after farrowing. Sows had free access to water at all times through a nipple waterer in 
their stalls. On Day 4 after farrowing, sow treatments began and continued for six days.  Sows 
assigned to the meloxicam-treatment group (n=5) received 30 mg/kg meloxicam (Meloxicam, 
Aurobindo Pharma, India, Batch X1513019-A, Expiration Date 2/2015), which was divided 
between 2 feedings at 0700h and 1600h. The meloxicam was ground from tablets into a 
powdered consistency using a commercial grinder (Spice & Nut Grinder, Cuisinart, East 
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Windsor, NJ), after which it was incorporated into each sow’s daily feed ration in a portable 
mixer (Kobalt Model #043206, Monarch Industries, Winnipeg, MB, Canada). Control sows 
(n=5) received 30 mg/kg of whey protein placebo (Health Watchers, Inc., Bohemia, NY), which 
is a pharmacologically inactive excipient used in the manufacturing of meloxicam tablets. The 
placebo was prepared in a separately marked bucket by thorough hand-mixing with gloved hands 
to prevent cross contamination.  
Animal phase study design 
The sows were allowed to farrow naturally without induction methods. They were then 
randomly assigned to two groups. The first sow to give birth was randomly allocated to the 
meloxicam-treated group (MEL), and the second sow was allocated to the whey placebo group 
(CONT). The alternating pattern continued for the remaining sows, based on the farrowing date. 
The day of farrowing was designated as “Day 0” for each sow and litter. The overall time 
scheme of activities, including drug administration and sample collection, is detailed in Figure 1.  
On Day 3, post-farrowing piglets in the litter were weighed and ranked in a descending order. In 
each litter, the heaviest three boars and three gilts were selected and ear tagged (Allflex Global 
Ear Tags, Allflex USA, Inc., DFW Airport, TX). The next three heaviest piglets, regardless of 
sex, were selected and tagged as sentinels to specifically measure the inhibition of plasma 
prostaglandin E2 (PGE2) levels and demonstrate the pharmacodynamic effect of meloxicam. In 
total, nine piglets per litter were tagged. Two litters did not have three live boar piglets. In those 
instances, all available boars were used as test piglets. In another litter, a male test piglet was laid 
on and subsequently died after being identified but before blood sampling began. No other 
piglets were substituted into the test category. Cross-fostering was not performed at any phase of 
the study.  
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Piglet processing occurred on Day 5 after farrowing. After a pre-processing blood draw, 
the boars were immediately castrated and tail-docked. They then received 1 mL (100 mg) iron 
IM (Ferrodex 100, AgriLabs, St. Joseph, MO). Castration was performed in accordance with 
standard swine industry practices by making two vertical incisions approximately 2-3 cm long in 
the scrotum with a number-ten scalpel blade and scalpel handle, marsupializing the testicles, and 
finally providing manual pressure on the spermatic cord until it separated from the piglet’s body.  
Immediately after each piglet castration, the scalpel blade and handle were immersed in a dilute 
chlorhexidine mixture for disinfection between each piglet procedure per typical swine industry 
practice.  All castrations were performed by a single experienced veterinarian to minimize 
variation (JLB). Gilts were handled in a similar manner, and they also underwent tail docking 
and received iron.  
Sow blood samples (8 mL/sample) were collected via the left or right jugular vein using a 
25.4-mm, 16-gauge hypodermic needle (Air-Tite Products, Virginia Beach, VA) and 12-mL 
Luer lock syringe (TycoHealth Care, Mansfield, MA). During blood collection, sows were 
manually restrained in their crates using a pig snare. Piglet blood samples (2 mL/sample) were 
collected using the left or right jugular vein using a 3.8-cm, 22-gauge hypodermic needle 
(TycoHealth Care, Mansfield, MA) and 3-mL syringe (TycoHealth Care, Mansfield, MA). These 
samples were obtained using physical restraint by placing the piglet in a supine position.  
On Day 8 after farrowing, sows were euthanized by a penetrating captive bolt, followed 
by exsanguination, and piglets were euthanized by blunt force trauma to the cranium, according 
to American Veterinary Medical Association guidelines [12]. Necropsies were performed on the 
sows and processed piglets. The liver, kidney, gastric fundus, duodenum, 
semitendinosus/semimembranosus muscle, and fat were collected for analysis. 
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Following processing and each blood-sampling time point, changes in piglet skin 
temperature were measured using a commercially available infrared thermography (IRT) camera 
(FLIR SC660, Systems, Wilsonville, OR). Prior to each use, the camera was allowed to self-
calibrate with the ambient temperature and relative humidity in the barn. Piglets were placed in a 
non-restrictive plastic tub measuring 50.8 cm in diameter and 43.2 cm tall for approximately ten 
seconds while thermographic images of the cranium, right and left ears, and snout were obtained 
(Figure 2). 
Sample collection, processing and analysis 
All drug concentrations in plasma were analyzed at the Iowa State University Veterinary 
Diagnostic Laboratory by the Iowa State University-Pharmacology Analytical Support Team 
(ISU-PhAST).  
Meloxicam analysis 
Blood for meloxicam analysis was placed in 10-mL and 3-mL heparinized blood 
collection tubes (BD Vacutainer, Franklin Lakes, NJ). Samples were centrifuged for 15 minutes 
at 1000 g at ambient temperature. The plasma was separated and placed into cryovials for storage 
at -80°C. 
Plasma concentrations of meloxicam were determined using high-performance liquid 
chromatography (HPLC) (Accela Pump and Autosampler, Thermo Scientific, San Jose, CA, 
USA) with mass spectrometry (MS) detection (LTQ XL, Thermo Scientific, San Jose, CA, 
USA). Plasma samples, plasma spikes, and plasma quality control (QC) samples (200 µL each) 
were treated with 1 M trichloroacetic acid (100 μL) after the addition of the internal standard, 
piroxicam (10 μL of 10 ng/μL). The samples were vortexed for 5 seconds and centrifuged for 20 
minutes at 2000 g to sediment the precipitate. A portion of the supernatant (150 μL) was 
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transferred to an injection vial that was fitted with a glass insert containing 100 μL of 1.9% 
ammonium hydroxide in 25% aqueous acetonitrile. The injection volume was set to 20 μL. The 
mobile phases consisted of 0.1% formic acid in water (A) and 0.1% formic acid in acetonitrile 
(B) at a flow rate of 0.250 mL/min. The mobile phase began at 40% B with a linear gradient to 
95% B at 4 minutes, which was maintained for 1.5 minutes, followed by re-equilibration to 40% 
B. Separation was achieved with a solid-core C18 column (KinetexXB -C18, 100 mm × 2.1 mm, 
2.6-µm particles, Phenomenex, Torrance, CA, USA) that was maintained at 45°C. Piroxicam 
eluted at 2.6 minutes, and meloxicam eluted at 3.3 minutes. A full scan MS of the 
pseudomolecular ions of piroxicam (m/z 332) and meloxicam (m/z 352) was used for analyte 
detection. The sum of the intensities of ions at m/z of 115 and 141 were used for meloxicam 
quantitation. The internal standard, piroxicam, was quantitated with the sum of the ion intensities 
at m/z of 95, 121, and 164. Sequences consisting of plasma blanks, calibration spikes, QC 
samples, and porcine plasma samples were processed in batches with a processing method that 
was developed in the Xcalibur software (Thermo Scientific, San Jose, CA, USA). The processing 
method automatically identified and integrated each peak in each sample and calculated the 
calibration curve based on a weighted (1/X) linear fit. Plasma concentrations of meloxicam in 
unknown samples were calculated by the Xcalibur software based on the calibration curve. 
Results were then viewed in the Quan Browser portion of the Xcalibur software. Fourteen 
calibration spikes were prepared in porcine plasma covering the concentration range of 1–20,000 
ng/mL. QC samples were prepared at concentrations of 15, 150, and 1500 ng/mL in duplicate 
with each set of samples. Calibration curves exhibited a correlation coefficient (R2) exceeding 
0.997 across the entire concentration range. The QC samples at 150 and 1500 ng/mL were within 
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2–8 % of their nominal values, and the low QC sample at 15 ng/mL differed from its nominal 
value by 10–15 %. 
PGE2 analysis 
PGE2 concentrations were determined using methods that were previously described[13]. 
Briefly, fresh piglet blood was collected into sterile tubes containing heparin. To stimulate ex-
vivo PGE2 production by monocytes, the heparinized whole blood was incubated for 24 hours at 
37°C with 10 µg/ml lipopolysaccharide (LPS, derived from Escherichia coli 055:B5, Sigma 
Aldrich, St. Louis, MO), which was diluted in phosphate-buffered saline (PBS). The first blood 
collection occurred prior to treatments and was divided into two equal aliquots: one was 
incubated with LPS, and the other was incubated with an equivalent volume of PBS. These 
aliquots were used as positive and negative controls. 
At the end of the incubation, all samples were centrifuged at 400 g for 10 minutes to 
obtain plasma: 250 μl of plasma were mixed with 1000 μl of methanol (1:5 dilution) to permit 
protein precipitation. After a final centrifugation at 3000 g for 10 minutes, supernatants were 
collected and stored at -80°C.  
The concentration of plasma PGE2 was determined using an enzyme-linked 
immunosorbent assay kit (Cayman Chemical, Co, Ann Arbor, MI). The calculated coefficient of 
variation for intra-assay variability was 11.7%, and the inter-assay variability was 9.2%.  
Cortisol analysis 
Blood for cortisol analysis was collected in a 3-mL heparinized blood collection tube 
(BD Vacutainer, Franklin Lakes, NJ) and then centrifuged for 10 minutes at 1500 g. The plasma 
was collected, immediately frozen, and stored at -80°C. Plasma samples were analyzed for 
66 
 
cortisol within 60 days after sample collection and within 10 consecutive days once analysis 
commenced. 
Plasma cortisol concentrations were determined using a commercial radioimmunoassay 
(RIA) kit (Coat-A-Count Cortisol, Siemens Medical Solutions Diagnostics [formally Diagnostic 
Products Corp.], Los Angeles, CA). Samples were incubated at 4°C for 2 hours to improve assay 
sensitivity. Samples were assayed in duplicate with the reported concentration equaling the 
average cortisol concentration between duplicates. The calculated coefficient of variation for 
intra-assay variability was 9.2%, and the inter-assay variability was 9.3%.  
Substance P Analysis 
Blood (1 mL) for substance P (SP) analysis was collected in a 4-mL potassium 
ethylenediaminetetraacetic acid (EDTA) purple-top blood collection tube (BD Vacutainer, 
Franklin Lakes, NJ) that was previously spiked with 50 µL benzamidine. This blood was 
promptly centrifuged for 15 minutes at 1000 g. The plasma was immediately frozen and stored at 
-80°C.  
The SP assay was performed as described by Liu et al.[14] with slight modifications 
using non-extracted plasma. Method validation using non-extracted plasma consisted of the 
complete recovery (±15%) of a known concentration of SP that was added to pooled baseline 
sample plasma. Samples were analyzed in duplicate with a double-antibody RIA using a primary 
antibody (polyclonal rabbit anti-SP; 1:20,000) from Phoenix Pharmaceutical, Inc. (Burlingame, 
CA, USA). EDTA (13 mM) and benzamidine (1 mM) were added as protease inhibitors. SP was 
assayed using the 125I-[Tyr8]-SP tracer (approximately 18000 cpm) (PerkinElmer, Inc., 
Waltham, MA, USA).  Samples were assayed in duplicate with the reported concentration 
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equaling the average substance P concentration between duplicates. The intra- and inter-assay 
coefficients of variation were 7.6% and 14.9%, respectively.  
Infrared Thermography Analysis 
Standardized anatomical locations on the pig were identified by a technician in IRT 
digital images that were obtained of study piglets. IRT images were converted to temperature 
readings by proprietary software that was calibrated internally by the machine and designed to 
interface specifically with the camera (Thermacam Researcher Pro 2.8 SR-1, FLIR Systems). 
Data were analyzed for changes in temperature by comparing temperature values obtained at 
consistent anatomical locations on the pig over the range of sample time points. Four anatomical 
locations in each image were initially converted to temperature readings, but variations in piglet 
position and orientation to the camera effectively reduced the sample size for ear and snout 
readings. Consequently, these were discarded, and the more accessible cranium location was 
forwarded to the statistical analysis phase of the study.  
Statistical analysis 
Data were analyzed using generalized linear mixed models fitted with the GLIMMIX 
procedure of SAS (SAS Institute Inc., Version 9.2). Treatment, procedure, time, and their 
interactions were used as fixed effects, whereas sow was a random effect, and piglet was the 
subject of repeated measures. A separate linear mixed model was run to study the effect of 
meloxicam concentrations on PGE2, substance P and IRT by using Meloxicam_Levels as an 
explanatory variable. Baseline measurements were used as covariates in the above models. 
Model assumptions were considered to be appropriately met, based on diagnostics that were 
conducted on studentized residuals. Estimated least square means and corresponding standard 
errors, or 95% confidence intervals, are presented. A significant difference was considered to 
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exist when p≤0.05, and a marginal difference was considered to exist when 0.05 < p≤0.10. 
Relevant pairwise comparisons were conducted when the significance of the interaction term was 
p≤0.10, using Tukey-Kramer adjustments as appropriate to avoid inflation of the Type I error 
rate due to multiple comparisons.  
Results and Discussion 
Plasma Meloxicam Concentration 
Meloxicam was detected in the plasma of all piglets in the MEL group at every time point 
after treatment commenced (Figure 3). The mean (±standard error of the mean [SEM]) 
meloxicam concentration at castration was 568.9 ±105.8 µg/mL. No meloxicam was found in the 
CONT piglet plasma. Plasma meloxicam concentrations in both sows and piglets maintained 
steady-state concentrations for the duration of the treatment period, and they began to decline 
only after 72 hours when the treatment was discontinued in the feed (Figure 3).   
The pharmacokinetics of meloxicam after oral administration to mature swine has 
recently been described [15]. However, this is the first peer-reviewed report of a study 
documenting the transfer of an NSAID from the sow to the piglet via the transmammary route. In 
a recent National Pork Board (NPB) report [16], Brown found that injectable meloxicam is 
transferred through the milk to piglets at processing. However, this transfer utilized a one-time 
intramuscular dose of 1 mg/kg meloxicam to each sow, which resulted in 2.647 ng/mL of 
meloxicam in the piglet serum at 5 hours after administration. Piglet plasma meloxicam levels in 
the NPB report were only measured out to this time point. Due to differences in routes of 
administration and study design, further comparisons cannot be made. Other species, such as 
cattle [6] and humans [7], [8], [9], [17], have demonstrated NSAID transfer through milk. The 
importance of this study was to confirm that the transmammary route of administration is 
69 
 
feasible in piglets. Further pharmacokinetic modeling and dose-titration studies are needed to 
apply this information for the benefit of commercial swine production.  
Meloxicam is an NSAID that is approved for swine in Canada and the EU. It is labeled 
for use in swine to treat non-infectious locomotor disorders by reducing the signs of lameness 
and inflammation. It is also used for adjunctive therapy in the treatment of puerperal septicemia 
and toxemia with appropriate antibiotic therapy and for the relief of post-operative pain 
associated with minor soft tissue surgery, such as castration [18]. Because no analgesic drugs are 
approved to provide pain relief to swine in the United States, the administration of meloxicam to 
swine constitutes extra-label drug use (ELDU). Under the Animal Medicinal Drug Use 
Clarification Act (AMDUCA), ELDU is permitted under veterinary supervision for the relief of 
suffering in swine when specific conditions are met[19]. In the absence of FDA-approved 
analgesic compounds in food animals, the use of oral meloxicam tablets for the alleviation of 
pain or stress in swine can be considered under AMDUCA. It is imperative to remember that the 
dose of oral meloxicam in this study was extrapolated from data from other species for proof of 
transfer. Pharmacokinetic analyses are pending and will assist in making further conclusions 
about the effective dose. However, at this time, the dose used in this study cannot be 
recommended for use in commercial swine operations due to lack of tissue residue data.  
PGE2  
PGE2 demonstrated a treatment effect (p=0.0059) with significant differences (p<0.05) at 
each time point, with the exception of 24 hours after drug administration commenced (p=0.0909) 
(Figure 4). However, using this analysis, there was no time-by-treatment interaction (p=0.1763) 
or effect of time (p=0.6064). Meloxicam concentration also had evidence of a negative 
association with plasma PGE2 concentrations (p=0.0048).  
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This inhibition of PGE2 by meloxicam was anticipated, as a result of the blockage of the 
arachidonic acid pathway and cyclooxygenase-2. Prostaglandins contribute to the amplification 
of pain signaling by increasing nociception sensitization [20]. As such, reducing PGE2 
concentrations would provide decreased nociception following noxious stimuli, such as 
castration. Mean piglet plasma PGE2 concentrations ranged from 66.2–719.9 pg/mL. These 
levels are much lower than those reported in equines (1.7 ng/mL), canines (329 ng/mL), and 
felines (0.7 ng/mL) [21]. No porcine comparisons are available in the literature. There are 
several potential explanations for the lower PGE2 levels. First, the piglets were relatively young 
and blood from these animals may not have fully responded to LPS stimulation. Second, other 
studies have used different strains or concentrations of LPS. Finally, we used ex vivo stimulation 
of whole blood, which may contribute to lower levels. Despite these species-specific differences, 
decreases in plasma PGE2 were observed at most time points in MEL piglets compared to CONT 
piglets.  This suggests that meloxicam was successfully transferred through milk to piglets at 
concentrations that likely provided analgesia based on the demonstrated ex-vivo inhibition of 
PGE2 production.  
Pain Biomarker Analysis 
Cortisol Analysis 
There was a time-by-treatment interaction for piglet plasma cortisol (p=0.0009) (Figure 
5). MEL piglets had lower plasma cortisol than CONT piglets for the first 10 hours after 
processing. Although no individual time points demonstrated significant differences, p values 
with marginal significance were observed at 1 and 6 hours after processing (p=0.10 and p=0.12, 
respectively) (Table 1).  
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These study findings are in agreement with several other studies that associate a decrease 
in piglet plasma cortisol with pain mitigation. This decrease was noted with various analgesics at 
castration, such as meloxicam [22], [3], both meloxicam and flunixin administered separately 
[23],[24], and both meloxicam and tolfenamic acid administered separately [4].  
The highest cortisol levels in both groups were observed at 60 minutes after castration. 
This peak is shown in Figure 5 and is consistent with previous studies showing that the highest 
cortisol levels are detected 30–90 minutes after processing [22], [25], [4], [23], [26], [27], [28].  
Glucocorticoids are secreted in response to a stressor, such as castration, and are generally 
considered to be indicative of stress and, thereby, pain. [27]. However, piglet plasma cortisol 
does have some limitations as an objective pain biomarker. For instance, stressors such as 
handling may cause an increase in plasma cortisol concentrations [29]. However, research by 
Prunier et al. [28] suggests that sham-castrated pigs have lower amplitudes and durations of 
cortisol than castrated piglets, and these are likely to be connected to pain or tissue damage [22]. 
A systematic review of pain management during routine management procedures highlighted the 
need for additional validation of pain biomarkers in peer-reviewed studies [30,31]. Until more 
pain biomarkers can be clearly described and validated, cortisol remains to be one of the most 
easily identifiable means of describing piglet pain.  
Substance P 
Measurements of SP indicated no differences between MEL and CONT piglets at 
processing (p=0.6733). There was a significant change in SP levels over time (p=0.0024). 
However, there were no significant interactions in procedure by time (p=0.66) or treatment by 
procedure by time (p=0.33) (Table 2). There was also no association between meloxicam and SP 
levels (p=0.1444). 
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SP is an 11-amino acid neuropeptide that regulates nocioreceptive neurons, which are 
involved in the integration of pain, stress, and anxiety [32], [33]. It has proinflammatory effects 
in immune and epithelial cells and participates in inflammatory diseases of the respiratory, 
gastrointestinal, and musculoskeletal systems[34]. 
These results are in agreement with a recent study by Sutherland et al. [25], in which no 
significant differences in SP levels between castrated and sham-castrated piglets were found. 
However, in bovines, Coetzee et al. [33] demonstrated that castrated calves have significantly 
elevated SP levels compared to their non-castrated counterparts. Although SP has the potential to 
accurately describe physiological pain, further research is needed to determine its value in swine. 
Infrared Thermography 
Example IRT images from a meloxicam-treated and placebo-treated control piglet after 
castration is presented in Figure 6 a-b. IRT demonstrated a significant time-by-treatment 
interaction in cranial temperature between MEL and CONT piglets (p=0.0148; Figure 7). The 
interaction was significant at all timepoints after castration (p<0.0001; Figure 7). After baseline 
measurements, CONT piglets had lower skin temperature than MEL piglets. There was a 
positive association between plasma meloxicam levels and cranial skin temperature (p=0.0345).  
Animals that are stressed or in pain can exhibit decreases in cutaneous temperature due to 
sympathetic nervous system activation, which causes vasoconstriction, shifting of the blood from 
the skin to the organs, and loss of heat in the periphery of the body[35], [36]. IRT has  been 
shown to be a valuable tool for pain assessment in beef and dairy calves by non-invasively 
measuring autonomic nervous system responses at the time of dehorning and castration  [36], 
[35], [37].  IRT was also used by Hansson et al.[24] to measure temperatures at 24 hours after 
piglet castration. Piglet ear temperature was found to be significantly higher in control piglets 
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versus those given either lidocaine or a lidocaine/meloxicam combination. In that same study, no 
significant differences were found when measuring the skin around the castration site. This one-
time measurement reflects the differences noted in this study up to 24 hours after castration 
(Figure 6) but fails to provide a longer duration depiction of piglet pain.  
Differences in IRT measurements in anatomical sites were noted. Cranial temperature 
was lower in CONT piglets. This significant time-by-treatment interaction (p=0.0148) suggests 
that this  would be an effective anatomical site for assessing the effect of pain on cutaneous 
perfusion However, there were no significant differences in temperature between treatment 
groups over time in the left ear (p=0.9744), right ear (p=0.7989), and snout tip (p=0.0936). There 
was also no association between plasma meloxicam concentrations and IRT measurements in the 
snout (p=0.8683), left ear (p=0.9141), and right ear (p=0.2029) (Table 2).  
Analysis of the ears and snout areas proved to be difficult, due to the image capture 
method. Thermography images were taken by placing each piglet in a small plastic tub to reduce 
any confounding stress that was associated with further handling after castration and blood 
sampling. It was challenging to obtain consistent images, due to the anatomical configuration of 
the folded-over, floppy ears on a relatively mobile piglet. Also, the snout may have been too 
sensitive to ambient temperature to provide a meaningful assessment of individual piglet pain. 
Therefore, for the purposes of this study, it was determined that cranial skin temperature was the 
most accurate anatomical location for assessing piglet pain responses after castration.  
The temperature measurement sites that were found to be useful in this study are in 
conflict with other studies using IRT. Schmidt et al.[38] found the eye and the back of the ear to 
be the most useful for assessing fever in sows. Additional sites in the literature include the 
mammary gland and vulva [39], [40]. However, these studies detected either fever response or 
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estrus onset in adult animals, which are likely different than pain-related thermoregulation 
processes in baby piglets.  
Temperature differences in the treatment groups are further accentuated in a circadian 
rhythm. Peak temperatures in both MEL and CONT piglets were noted in the evening 
measurements at 12, 36, and 60 hours after castration. Trough temperatures were seen in 
morning measurements at 24, 48, and 96 hours after castration (Figure 6). Similar temperature 
circadian trends have long been noted in livestock, and they were recently demonstrated in dairy 
cows [41].  
Measurement of piglet body temperature using IRT shows promise as a piglet pain 
biomarker by demonstrating differences in cranial temperature. This non-invasive method allows 
pain to be assessed for up to 72 hours after castration. 
This study is the first peer-reviewed report of the successful transmammary transfer of 
meloxicam in milk from sows to piglets. Piglet plasma cortisol levels and cranial IRT 
measurements demonstrated significant changes as a result of analgesic treatment with 
meloxicam. The novel administration of analgesic drugs via transmammary transfer has 
significant potential benefits for the swine industry. As one litter is medicated through the oral 
treatment of one sow, large numbers of piglets can receive pre-emptive analgesia without the 
need for additional handling and injections. This will also lead to reduced animal stress, 
improved safety for both the pig and handler, and a reduced potential for tissue lesions and drug 
residues when the injections are removed. Future research investigations can focus on providing 
data for meloxicam dose refinement and validating physiological pain indicators.  
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TABLE 1.  Mean plasma cortisol concentrations (± SEM) after processing in piglets treated with 
meloxicam (MEL) or whey (WHEY) placebo.   
 
MEL WHEY 
 
Time  
Plasma Cortisol 
(ng/mL) 
Plasma Cortisol 
(ng/mL) p 
1 h 91.18 ± 9.43 108.15 ± 8.96 0.12 
6 h 56.46 ± 6.07 64.36 ± 4.63 0.10 
12 h 45.45 ± 5.29 41.30 ± 3.65 0.74 
24 h 35.38 ± 3.65 26.86 ± 2.79 0.37 
36 h 35.86 ± 3.90 42.49 ± 4.85 0.15 
48 h 34.83 ± 3.68 30.99 ± 3.75 0.78 
60 h 40.86 ± 5.15 29.36 ± 3.27 0.45 
72 h 30.98 ± 2.92 32.66 ± 4.80 0.73 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
TABLE 2. Comparison between the least squares (LS) means ± standard error (SE) of piglet serum chemistry biomarkers and infrared 
thermography (IRT) temperatures, as classified by the procedure (Proc) of castrated (CAST) and sham castrated (SHAM) and 
treatment (Trt) with 30 mg/kg PO meloxicam (MEL) or whey placebo (CONT) to sows on Days 4–6 after farrowing.  
 
       Experimental Group 
Calculated Means (± SEM)  P VALUES 
Proc CAST SHAM (model adjusted) 
Trt CONT MEL CONT MEL           
Parameter 
LS 
Means 
± SE 
LS 
Means 
± SE 
LS 
Means 
± SE 
LS 
Means 
± SE Time Trt TimeXTrt ProcXTime TrtXProcXTime 
Average 
Cortisol, 
ng/mL 
48`.9 
±3.49 
50.41 
±3.82 
43.71 
±2.96 
44.53 
±2.73 
<0.0001 0.65 0.0009 0.14 0.39 
Average 
Substance 
P, pg/mL 
89.24 
±4.34 
95.59 
±2.54 
81.13 
±3.52 
96.60 
±3.48 
0.0024 0.35 0.67 0.66 0.33 
Left Ear 
Temp, °C 
32.06 
±0.30 
32.42 
±0.26 
32.56 
±0.30 
32.35 
±0.26 
<0.0001 0.85 0.97 0.73 0.96 
Right Ear 
Temp, °C 
34.37 
±0.22 
33.80 
±0.23 
34.07 
±0.22 
33.85 
±0.21 
<0.0001 0.69 0.80 0.58 0.74 
Snout 
Temp, °C 
31.56 
±0.25 
32.40 
±0.23 
32.10 
±0.25 
31.93 
±0.25 
<0.0001 0.79 0.09 0.63 0.49 
Cranium 
Temp, °C 
37.35 
±0.10 
37.55 
±0.08 
37.35  
±0.09 
37.47 
±0.08 
<0.0001 0.32 0.01 0.87 0.99 
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 FIGURE 1. Outline of study events for sows and their litters. 
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FIGURE 2. Example of a digital image of infrared thermography (IRT) measurement. Each 
processed piglet was measured for temperature in ⁰C at the top of the cranium (circled), right and 
left ears, and snout (cross marks). 
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FIGURE 3. Comparison of plasma meloxicam concentrations from sows and their piglets treated 
with 30 mg/kg meloxicam. The mean (±SEM) meloxicam levels at 24 hours (piglet processing) 
were 568.9 ±105.8 µg/mL. No meloxicam was found in CONT piglet plasma. Both sow and 
piglet plasma meloxicam concentrations maintained relatively constant levels for the duration of 
the treatment period, and they began to decline only after 72 hours when the treatment was 
discontinued in the feed. 
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FIGURE 4. Plasma PGE2 ± SE levels from meloxicam (MEL) - and whey placebo (CONT) - 
treated piglets. MEL piglets had a significantly greater amount of prostaglandin E2 (PGE2) 
inhibition compared to their CONT counterparts (p=0.0059). All time points that are marked 
with a and b were significantly different (p<0.05). The exception was 24 hours after 
administration (p=0.0909).  
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FIGURE 5. Processed plasma cortisol concentrations after the treatment of sows with 30 mg/kg 
meloxicam (MEL) or whey placebo (CONT). Means ± SE are depicted.  
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FIGURE 6 a- b. Example IRT images from a meloxicam-treated (a) and placebo-treated control 
piglet (b) after castration.  Color differences reflect activation of the sympathetic nervous system 
leading to peripheral vasoconstriction and a localized decrease in skin temperature.  Figure 6a 
demonstrates a meloxicam-treated piglet with a higher (red) cranial skin temperature than the 
cranial skin temperature (yellow) of the whey-treated piglet.  
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FIGURE 7. Cranial infrared thermography (IRT) from meloxicam (MEL)- and whey placebo 
(CONT)- treated piglets. Means ± SE are depicted. There is a significant time-by-treatment 
interaction between MEL and CONT piglets (p=0.0148). The interaction was significant at all 
timepoints (p<0.0001). There was an association between plasma meloxicam levels and cranial 
IRT measures (p=0.0345). 
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CHAPTER 4. GENERAL CONCLUSIONS 
 
This study marks the first successful proof of concept of transmammary drug transfer 
between the sow to her piglets after an oral administration.  Not only was the concept of 
administering an oral medication to sows for it to effectively transfer to piglets through milk 
proven, novel physiology information as it relates to piglet pain has been created.   
When sows were administered meloxicam in their daily rations, meloxicam was 
transferred into their plasma at mean concentrations (±SEM) of 568.9 (105.8) µg/mL.  These 
levels significantly inhibited PGE2 in MEL piglets when compared with CONT piglets.  Both the 
established parameter of plasma cortisol, along with the novel method of IRT described the 
degree of pain alleviation in castrated piglets with the administration of meloxicam.  Finally, sow 
pharmacokinetic parameters were described with the oral administration.  
It is clear the United States swine industry must become increasingly proactive in the area 
of pain control.  Swine veterinarians are professionally and ethically responsible the wellbeing 
and alleviation of pain reduction in their patients, yet there are no approved analgesics are 
available in this country.  This study demonstrates great potential for the novel method of 
transmammary analgesia.  As one litter is medicated through the oral treatment of one sow, large 
numbers of piglets can receive pre-emptive analgesia without the need for additional handling 
and injections. This will also lead to reduced animal stress, improved safety for both the pig and 
handler, and a decreased potential for tissue lesions and drug residues when the injections are 
removed.  
However, the results of this study do offer some cautionary points that preclude any 
immediate application of the transmammary method.  The sow oral dose must be amended to 
reduce the gastrointestinal pathology noted both sows and piglets.  Additionally, the lack of 
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approved analgesics in swine presents a conundrum.  Provisions for ELDU are made through 
AMDUCA under certain specific conditions within the context of a VCPR.  However, ELDU is 
limited to circumstances using approved drugs when the health of an animal is threatened, or 
suffering or death may result from failure to treat.  This means that ELDU to enhance production 
is not permitted. Debate exists in the industry whether castration should be described as a welfare 
practice or production practice.  Both sides have valid arguments and there has been no clear 
resolution from regulatory authorities.  Furthermore, ELDU in feed is expressly prohibited in the 
United States.  Finally, there is no established meat withdrawal to enable swine treated with oral 
meloxicam to enter the food chain.  Given these scientific and regulatory constraints, the 
transmammary method is not allowable at the present time in commercial swine systems. 
Despite several yet undiscovered pharmacologic aspects and regulatory issues of 
transmammary analgesia, the swine industry’s charge to maintain high standards of animal 
welfare remains constant. This study provides a robust foundation for further research in the field 
of pain alleviation, which will potentially lead to the approval of swine analgesics in the United 
States.   
 
 
 
 
